Form D · Other Technology
Neurawell Therapeutics, Inc.
Sunny Isles Beach, FL · CIK 0002026298
Offering snapshot reported Jun 10, 2024 · SEC filing
- Reported sold
- $1.62M Offering amount: $3M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 20, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 10, 2024 | Initial | $1,619,999 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-515484
Source: Form D, filed Jun 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Magid Abraham | Director, Executive |
| Jack Abraham | Director |
| Tom Insel | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
18501 Collins Ave, #4301
Sunny Isles Beach, FL, 33160
Sunny Isles Beach, FL, 33160